BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

493 related articles for article (PubMed ID: 24821329)

  • 1. Aggressive pituitary adenomas--diagnosis and emerging treatments.
    Di Ieva A; Rotondo F; Syro LV; Cusimano MD; Kovacs K
    Nat Rev Endocrinol; 2014 Jul; 10(7):423-35. PubMed ID: 24821329
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Refractory pituitary adenoma: a novel classification for pituitary tumors.
    Dai C; Feng M; Liu X; Ma S; Sun B; Bao X; Yao Y; Deng K; Wang Y; Xing B; Lian W; Zhong D; Ma W; Wang R
    Oncotarget; 2016 Dec; 7(50):83657-83668. PubMed ID: 27845901
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinically aggressive phenotype: A clinicopathological case series of atypical pituitary adenomas.
    Lv L; Hu Y; Yin S; Wang M; Zhou P; Zhang N; Ma W; Zhang S; Jiang S
    Clin Neurol Neurosurg; 2018 Apr; 167():93-98. PubMed ID: 29471288
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of pituitary carcinomas and atypical pituitary adenomas: a review.
    Hirohata T; Ishii Y; Matsuno A
    Neurol Med Chir (Tokyo); 2014; 54(12):966-73. PubMed ID: 25446382
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aggressive pituitary tumors.
    Chatzellis E; Alexandraki KI; Androulakis II; Kaltsas G
    Neuroendocrinology; 2015; 101(2):87-104. PubMed ID: 25571935
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Giant pituitary adenomas: pathologic-radiographic correlations and lack of role for p53 and MIB-1 labeling.
    Madsen H; Borges TM; Knox AJ; Michaelis KA; Xu M; Lillehei KO; Wierman ME; Kleinschmidt-DeMasters BK
    Am J Surg Pathol; 2011 Aug; 35(8):1204-13. PubMed ID: 21753697
    [TBL] [Abstract][Full Text] [Related]  

  • 7. p53 expression in pituitary adenomas and carcinomas: correlation with invasiveness and tumor growth fractions.
    Thapar K; Scheithauer BW; Kovacs K; Pernicone PJ; Laws ER
    Neurosurgery; 1996 Apr; 38(4):765-70; discussion 770-1. PubMed ID: 8692397
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early recognition of aggressive pituitary adenomas: a single-centre experience.
    Ceccato F; Regazzo D; Barbot M; Denaro L; Emanuelli E; Borsetto D; Rolma G; Alessio L; Gardiman MP; Lombardi G; Albiger N; D'Avella D; Scaroni C
    Acta Neurochir (Wien); 2018 Jan; 160(1):49-55. PubMed ID: 29170844
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New WHO classification of pituitary adenomas (4th edition): assessment of pituitary transcription factors and the prognostic histological factors.
    Nishioka H; Inoshita N
    Brain Tumor Pathol; 2018 Apr; 35(2):57-61. PubMed ID: 29318396
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Progress of Immunotherapy in Refractory Pituitary Adenomas and Pituitary Carcinomas.
    Dai C; Liang S; Sun B; Kang J
    Front Endocrinol (Lausanne); 2020; 11():608422. PubMed ID: 33362722
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aggressive Pituitary Adenomas: The Dark Side of the Moon.
    Priola SM; Esposito F; Cannavò S; Conti A; Abbritti RV; Barresi V; Baldari S; Ferraù F; Germanò A; Tomasello F; Angileri FF
    World Neurosurg; 2017 Jan; 97():140-155. PubMed ID: 27713064
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ki-67 labeling index and expression of p53 are non-predictive for invasiveness and tumor size in functional and nonfunctional pituitary adenomas.
    Grimm F; Maurus R; Beschorner R; Naros G; Stanojevic M; Gugel I; Giese S; Bier G; Bender B; Honegger J
    Acta Neurochir (Wien); 2019 Jun; 161(6):1149-1156. PubMed ID: 31037500
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Typical and atypical pituitary adenomas: a single-center analysis of outcome and prognosis.
    Chiloiro S; Doglietto F; Trapasso B; Iacovazzo D; Giampietro A; Di Nardo F; de Waure C; Lauriola L; Mangiola A; Anile C; Maira G; De Marinis L; Bianchi A
    Neuroendocrinology; 2015; 101(2):143-50. PubMed ID: 25633744
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Histone acetylation patterns of typical and atypical pituitary adenomas indicate epigenetic shift of these tumours.
    Ebrahimi A; Schittenhelm J; Honegger J; Schluesener HJ
    J Neuroendocrinol; 2011 Jun; 23(6):525-30. PubMed ID: 21453398
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biomarkers of aggressive pituitary adenomas.
    Mete O; Ezzat S; Asa SL
    J Mol Endocrinol; 2012 Oct; 49(2):R69-78. PubMed ID: 22822048
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular status of pituitary carcinoma and atypical adenoma that contributes the effectiveness of temozolomide.
    Matsuno A; Murakami M; Hoya K; Yamada SM; Miyamoto S; Yamada S; Son JH; Nishido H; Ide F; Nagashima H; Sugaya M; Hirohata T; Mizutani A; Okinaga H; Ishii Y; Tahara S; Teramoto A; Osamura RY
    Med Mol Morphol; 2014 Mar; 47(1):1-7. PubMed ID: 23955641
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MGMT immunoexpression in growth hormone-secreting pituitary adenomas and its correlation with Ki-67 labeling index and cytokeratin distribution pattern.
    Zuhur SS; Tanik C; Karaman Ö; Velet S; Çil E; Öztürk FY; Özkayalar H; Müslüman AM; Altuntaş Y
    Endocrine; 2011 Oct; 40(2):222-7. PubMed ID: 21792693
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pituitary carcinomas and aggressive pituitary tumours: merits and pitfalls of temozolomide treatment.
    Raverot G; Castinetti F; Jouanneau E; Morange I; Figarella-Branger D; Dufour H; Trouillas J; Brue T
    Clin Endocrinol (Oxf); 2012 Jun; 76(6):769-75. PubMed ID: 22404748
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Labeling index in pituitary adenomas evaluated by means of MIB-1: is there a prognostic role? A critical review.
    de Aguiar PH; Aires R; Laws ER; Isolan GR; Logullo A; Patil C; Katznelson L
    Neurol Res; 2010 Dec; 32(10):1060-71. PubMed ID: 20483025
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [New aspects of tumor pathology of the pituitary].
    Saeger W
    Pathologe; 2015 May; 36(3):293-300. PubMed ID: 25947224
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.